<div><div></div><div><span><p><strong><span>Esperion received Bundeskartellamt clearance for its planned merger and is proceeding toward a July 8 stockholder vote.</span></strong></p><p><strong><span>Key Highlights:</span></strong></p><ul><li><span>Bundeskartellamt cleared the merger with Essence Parent Inc. effective June 2, 2026, removing a key regulatory hurdle.</span></li><li><span>Closing still requires other conditions, including HSR waiting periods and stockholder adoption of the merger agreement.</span></li><li><span>Special meeting of stockholders to vote on the merger is scheduled virtually for July 8, 2026 at 8:00 a.m. ET.</span></li><li><span>Company warns transaction remains subject to customary risks and other closing requirements described in its proxy materials.</span></li></ul><p><span>Original SEC Filing: </span>Esperion Therapeutics, Inc. [ ESPR ] - 8-K - Jun. 09, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

ESPR

<p>Esperion Therapeutics received clearance from the German Bundeskartellamt for its merger with Essence Parent Inc. The company is now preparing for a virtual stockholder vote scheduled for July 8, 2026. While this regulatory hurdle is cleared, the transaction still requires completion of HSR waiting periods and final stockholder approval to close.</p>

Esperion cleared for merger by German antitrust authority; stockholder vote set for July 8